Your browser doesn't support javascript.
loading
Niosome-encapsulated auraptene reduced the mRNA expression of VEGF-A and PDGFs genes in human retina-derived RPE cell line.
Vahidi, Akram; Khosravi, Teymoor; Dastaviz, Farzad; Sheikh Arabi, Mehdi; Khosravi, Ayyoob; Oladnabi, Morteza.
Affiliation
  • Vahidi A; Student Research Committee, Golestan University of Medical Sciences, Gorgan 4934174611, Iran.
  • Khosravi T; Student Research Committee, Golestan University of Medical Sciences, Gorgan 4934174611, Iran.
  • Dastaviz F; Student Research Committee, Golestan University of Medical Sciences, Gorgan 4934174611, Iran.
  • Sheikh Arabi M; Department of Medical Nanotechnology, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan 4934174611, Iran.
  • Khosravi A; Stem Cell Research Center, Golestan University of Medical Sciences, Gorgan 4934174611, Iran.
  • Oladnabi M; Department of Molecular Medicine, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan 4934174611, Iran.
Int J Ophthalmol ; 17(6): 1028-1035, 2024.
Article in En | MEDLINE | ID: mdl-38895680
ABSTRACT

AIM:

To evaluate the effect of auraptene (AUR) treatment in forms of free and encapsulated in niosome nanoparticles by investigating the mRNA expression level of vascular endothelium growth factor (VEGF)-A and platelet-derived growth factors (PDGFs) in human retinal pigment epithelium (RPE) cell line.

METHODS:

Niosome nanocarriers were produced using two surfactants Span 60 and Tween 80. RPE cell line was treated with both free AUR and niosome-encapsulated. Optimum dosage of treatments was calculated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Expression of VEGF-A and PDGF-A, PDGF-B, PDGF-C, PDGF-D genes was measured after total RNA extraction and cDNA synthesis, using real-time polymerase chain reaction (RT-PCR).

RESULTS:

The highest entrapment efficiency (EE) was achieved by Span 60cholesterol (11) with 64.3%. The half maximal inhibitory concentration (IC50) of free and niosome-encapsulated AUR were 38.5 and 27.78 µg/mL, respectively. Release study revealed that niosomal AUR had more gradual delivery to the cells. RT-PCR results showed reduced expression levels of VEGF-A, PDGF-A, PDGF-B, PDGF-C, and PDGF-D after treatment with both free and niosomal AUR.

CONCLUSION:

Niosomal formulation of Span 60 cholesterol (11) is an effective drug delivery approach to transfer AUR to RPE cells. VEGF-A, PDGF-A, PDGF-B, PDGF-C, and PDGF-D are four angiogenic factors, inhibiting which by niosomal AUR may be effective in age-related macular degeneration.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int J Ophthalmol Year: 2024 Document type: Article Affiliation country: Country of publication:

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Int J Ophthalmol Year: 2024 Document type: Article Affiliation country: Country of publication: